RVRCOTCPharmaceutical PreparationsFiscal year ends December 31
Revium Rx.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.43+0.00 (0.00%)
Close on Oct 16, 2026
- Market cap
- $86.84M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.91 (+175.0%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $86.84M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 15.74
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$13.45M
- EPS, diluted
- -$0.22
- Book value per share
- $0.09
- Diluted shares
- 61M
Two years at a glance
Fiscal years 2024 to 2025, USD
Net income
-$13.45M
EPS, diluted
-$0.22
Reported period